Skiplinks

Medicine put to the test

As an independent scientific institute, IQWiG examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Tenofovir alafenamide in chronic hepatitis B: added benefit not proven, data incomplete

2017-07-03 No added benefit can be derived from the incompletely submitted data for adolescents or adults. The postulated better tolerability is not proven.  read more Link to "Tenofovir alafenamide in chronic hepatitis B: added benefit not proven, data incomplete"

Secukinumab and ixekizumab in psoriasis: considerable added benefit for certain patients

2017-06-01 There were notably more remissions than under the comparator therapies. In future, the analysis of symptoms should not be limited to improvements at one time point.  read more Link to "Secukinumab and ixekizumab in psoriasis: considerable added benefit for certain patients"

Pembrolizumab in non-small cell lung cancer: hint of considerable added benefit

2017-05-15 Good study design allows identification of the relevant subpopulation, in which prolonged overall survival notably outweighs disadvantages in some side effects.  read more Link to "Pembrolizumab in non-small cell lung cancer: hint of considerable added benefit"

High-risk medical devices: IQWiG sees no potential in 6 of 8 cases

2017-03-17 Only case series without informative value are available for most indications. A plausible mode of action is insufficient to attribute a potential.  read more Link to "High-risk medical devices: IQWiG sees no potential in 6 of 8 cases"

MRI-guided high-intensity focused ultrasound therapy for uterine fibroids has potential

2017-03-13 IQWiG has attributed a potential for a benefit to a new treatment method according to §137e SGB V. A testing study has been initiated. Numerous other assessments had no consequences.  read more Link to "MRI-guided high-intensity focused ultrasound therapy for uterine fibroids has potential"

loading …

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

No. Title Type Deadline
S16-05 Screening for depression on the report plan 2017-09-11
N16-02 Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heart failure on the preliminary report 2017-09-05

Commissions advertised

Commissions advertised

Currently no commissions advertised.


Easily understandable information for patients and the general community

Tenofovir alafenamide (Vemlidy) for chonic hepatitis B

The drug tenofovir alafenamide (trade name: Vemlidy) has been approved in Germany since January 2017 for the treatment of chronic hepatitis B. It is an option for adults and teenagers over the age of 12.  read more (Link to "Tenofovir alafenamide (Vemlidy) for chonic hepatitis B" – opens in a new window)

to top

Glossary entries